Published in Chest on February 01, 2012
Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 5.88
The Diagnosis and Treatment of Peripheral Arterial Vascular Disease. Dtsch Arztebl Int (2016) 1.33
Caring for the older person with chronic obstructive pulmonary disease. JAMA (2012) 0.96
A review of the role of anticoagulation in the treatment of peripheral arterial disease. Int J Angiol (2012) 0.85
Clinician's guide to the updated ABCs of cardiovascular disease prevention. J Am Heart Assoc (2014) 0.82
Aspirin for primary prevention of cardiovascular disease. Thromb J (2015) 0.82
Effects of Intravenous and Catheter Directed Thrombolytic Therapy with Recombinant Tissue Plasminogen Activator (Alteplase) in Non-Traumatic Acute Limb Ischemia; A Randomized Double-Blind Clinical Trial. Bull Emerg Trauma (2015) 0.80
Race as a predictor of delay from diagnosis to endarterectomy in clinically significant carotid stenosis. J Vasc Surg (2015) 0.79
Catheter-directed thrombolysis for acute limb ischaemia: An audit. Australas Med J (2014) 0.78
Pharmacology in peripheral arterial disease: what the interventional radiologist needs to know. Semin Intervent Radiol (2014) 0.75
Role of Cilostazol Therapy in Hemodialysis Patients with Asymptomatic Peripheral Arterial Disease: A Retrospective Cohort Study. Biomed Res Int (2016) 0.75
Systematic reviews and meta-analyses for more profitable strategies in peripheral artery disease. Ann Med (2014) 0.75
Antithrombotic therapy for secondary prevention of atherothrombotic events in cerebrovascular disease. Nat Rev Cardiol (2016) 0.75
Iloprost as an acute kidney injury-triggering agent in severely atherosclerotic patients. Cardiovasc J Afr (2016) 0.75
The dogma of aspirin: a critical review of evidence on the best monotherapy after dual antiplatelet therapy. Thromb J (2015) 0.75
Efficacy and safety of aspirin in patients with peripheral vascular disease: An updated systematic review and meta-analysis of randomized controlled trials. PLoS One (2017) 0.75
Inappropriate prescribing of antithrombotic therapy in Ethiopian elderly population using updated 2015 STOPP/START criteria: a cross-sectional study. Clin Interv Aging (2016) 0.75
Dual antiplatelet therapy is associated with prolonged survival after lower extremity revascularization. J Vasc Surg (2016) 0.75
Primary and secondary prevention of cardiovascular disease in patients with hyperlipoproteinemia (a). Clin Res Cardiol Suppl (2017) 0.75
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med (2006) 18.25
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet (1996) 16.32
Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg (2007) 14.17
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet (2009) 13.64
Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet (2010) 13.13
Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet (2010) 11.00
Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis. JAMA (2008) 7.84
Relationship of high and low ankle brachial index to all-cause and cardiovascular disease mortality: the Strong Heart Study. Circulation (2004) 6.15
Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. N Engl J Med (2007) 3.74
A comparison of recombinant urokinase with vascular surgery as initial treatment for acute arterial occlusion of the legs. Thrombolysis or Peripheral Arterial Surgery (TOPAS) Investigators. N Engl J Med (1998) 3.58
Exercise rehabilitation programs for the treatment of claudication pain. A meta-analysis. JAMA (1995) 3.57
Is a subgroup effect believable? Updating criteria to evaluate the credibility of subgroup analyses. BMJ (2010) 3.54
Ankle-arm index as a predictor of cardiovascular disease and mortality in the Cardiovascular Health Study. The Cardiovascular Health Study Group. Arterioscler Thromb Vasc Biol (1999) 3.36
Predictive value of noninvasive measures of atherosclerosis for incident myocardial infarction: the Rotterdam Study. Circulation (2004) 2.90
Effect of aspirin on mortality in the primary prevention of cardiovascular disease. Am J Med (2011) 2.65
Use of ankle brachial pressure index to predict cardiovascular events and death: a cohort study. BMJ (1996) 2.58
Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial. J Vasc Surg (2010) 2.52
From effect size into number needed to treat. Lancet (1999) 2.41
Efficacy of oral anticoagulants compared with aspirin after infrainguinal bypass surgery (The Dutch Bypass Oral Anticoagulants or Aspirin Study): a randomised trial. Lancet (2000) 2.19
Recombinant tissue-type plasminogen activator versus urokinase in peripheral arterial and graft occlusions: a randomized trial. Radiology (1990) 2.14
Nd:YAG laser with sapphire tip combined with balloon angioplasty in peripheral arterial occlusions. Long-term results. Circulation (1991) 2.06
Prevalence of asymptomatic carotid artery stenosis in the general population: an individual participant data meta-analysis. Stroke (2010) 1.97
Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl: a meta-analysis. Arch Intern Med (1999) 1.81
Routine stent implantation vs. percutaneous transluminal angioplasty in femoropopliteal artery disease: a meta-analysis of randomized controlled trials. Eur Heart J (2008) 1.71
Thrombolysis or peripheral arterial surgery: phase I results. TOPAS Investigators. J Vasc Surg (1996) 1.70
A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. Arch Intern Med (1999) 1.41
Non-invasively detected carotid stenosis and ischaemic heart disease in men with leg arteriosclerosis. Lancet (1993) 1.38
A comparison of thrombolytic therapy with operative revascularization in the initial treatment of acute peripheral arterial ischemia. J Vasc Surg (1994) 1.26
Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. J Vasc Surg (1998) 1.20
Efficacy of cilostazol in reducing restenosis in patients undergoing contemporary stent based PCI: a meta-analysis of randomised controlled trials. EuroIntervention (2009) 1.20
Controlled trial of aspirin in cerebral ischemia. Part II: surgical group. Stroke (1978) 1.19
Pooling health-related quality of life outcomes in meta-analysis-a tutorial and review of methods for enhancing interpretability. Res Synth Methods (2011) 1.15
Acute limb ischemia. Tech Vasc Interv Radiol (2009) 1.14
A comparison of cilostazol and pentoxifylline for treating intermittent claudication. Am J Med (2000) 1.12
Antiplatelet treatment prolongs survival after carotid bifurcation endarterectomy. Analysis of the clinical series followed by a controlled trial. Ann Surg (1990) 1.12
Danish very-low-dose aspirin after carotid endarterectomy trial. Stroke (1988) 1.10
Cessation of smoking in patients with intermittent claudication. Effects on the risk of peripheral vascular complications, myocardial infarction and mortality. Acta Med Scand (1987) 1.07
Analysis of the cilostazol safety database. Am J Cardiol (2001) 1.04
Cilostazol for peripheral arterial disease. Cochrane Database Syst Rev (2008) 1.03
Surgery versus thrombolysis for acute limb ischaemia: initial management. Cochrane Database Syst Rev (2002) 1.02
Antiplatelet drugs in femoropopliteal vein bypasses: a multicenter trial. J Vasc Surg (1991) 1.01
Effect of aspirin and dipyridamole on the patency of lower extremity bypass grafts. Surgery (1984) 1.01
Effect of cilostazol in patients with intermittent claudication: a randomized, double-blind, placebo-controlled study. Vasc Endovascular Surg (2002) 0.99
Effects of aspirin and dipyridamole on expanded polytetrafluoroethylene graft patency. Surgery (1982) 0.97
Antiplatelet and anticoagulant drugs for prevention of restenosis/reocclusion following peripheral endovascular treatment. Cochrane Database Syst Rev (2005) 0.97
Proper evaluation and management of acute embolic versus thrombotic limb ischemia. Semin Vasc Surg (2009) 0.97
Drug therapy for improving walking distance in intermittent claudication: a systematic review and meta-analysis of robust randomised controlled studies. Eur J Vasc Endovasc Surg (2009) 0.95
Benefits, morbidity, and mortality associated with long-term administration of oral anticoagulant therapy to patients with peripheral arterial bypass procedures: a prospective randomized study. J Vasc Surg (2002) 0.95
Warfarin improves the outcome of infrainguinal vein bypass grafting at high risk for failure. J Vasc Surg (1998) 0.93
Prostanoids for critical limb ischaemia. Cochrane Database Syst Rev (2010) 0.92
Long-term safety of cilostazol in patients with peripheral artery disease: the CASTLE study (Cilostazol: A Study in Long-term Effects). J Vasc Surg (2007) 0.90
Random control trial of a short course of aspirin and dipyridamole (Persantin) for femorodistal grafts. Br J Surg (1987) 0.90
Reocclusion prophylaxis with dipyridamole combined with acetylsalicylic acid following PTA. Angiology (1990) 0.89
Antiplatelet therapy for preventing stroke and other vascular events after carotid endarterectomy. Cochrane Database Syst Rev (2003) 0.88
Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular disease. Cochrane Database Syst Rev (2007) 0.88
A systematic review and economic evaluation of cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease. Health Technol Assess (2011) 0.88
Thienopyridine derivatives versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients. Cochrane Database Syst Rev (2009) 0.87
Does low-dose acetylsalicylic acid prevent stroke after carotid surgery? A double-blind, placebo-controlled randomized trial. Stroke (1993) 0.84
Surgical treatment versus thrombolysis in acute arterial occlusion: a randomised controlled study. Eur J Vasc Surg (1992) 0.83
The vascular and biochemical effects of cilostazol in patients with peripheral arterial disease. J Vasc Surg (2009) 0.82
Failure of aspirin plus dipyridamole to prevent restenosis after carotid endarterectomy. Ann Intern Med (1992) 0.82
Anticoagulants (heparin, low molecular weight heparin and oral anticoagulants) for intermittent claudication. Cochrane Database Syst Rev (2001) 0.80
Recombinant tissue plasminogen activator versus urokinase for local thrombolysis of femoropopliteal occlusions: a prospective, randomized multicenter trial. J Endovasc Ther (2001) 0.80
Antiplatelet agents for preventing thrombosis after peripheral arterial bypass surgery. Cochrane Database Syst Rev (2008) 0.80
Potential use of a low-molecular-weight heparin to prevent restenosis in patients with extensive wall damage following peripheral angioplasty. Angiology (2001) 0.80
Efficacy of low-molecular-weight heparin in the management of intermittent claudication. Angiology (1991) 0.79
Platelet inhibition with ASA/dipyridamole after percutaneous balloon angioplasty in patients with symptomatic lower limb arterial disease. A prospective double-blind trial. Study group on pharmacological treatment after PTA. Eur J Vasc Surg (1994) 0.79
Clinical assessment of low molecular weight heparin effects in peripheral vascular disease. Angiology (1993) 0.78
Comparison of tissue plasminogen activator and urokinase in the local infiltration thrombolysis of peripheral arterial occlusions. Eur J Radiol (1996) 0.78
Fibrinolytic agents for peripheral arterial occlusion. Cochrane Database Syst Rev (2010) 0.78
A new low molecular weight heparin in the treatment of peripheral arterial disease. Int Angiol (1989) 0.77
Randomized trial of the effects of low-dose calcium-heparin in patients with peripheral arterial disease and claudication. Italian CAP Study Group. Am J Med (1999) 0.77
Low-dose aspirin combined with dipyridamole versus anticoagulants after femoropopliteal percutaneous transluminal angioplasty. Radiology (1994) 0.76
Indobufen versus placebo in the prevention of restenosis after carotid endarterectomy: a double-blind pilot study. J Int Med Res (1991) 0.76
Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 56.72
Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 41.47
Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med (2008) 31.57
Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 26.95
Grading quality of evidence and strength of recommendations. BMJ (2004) 26.08
Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. Lancet (2005) 17.08
Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 16.17
Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet (2011) 13.25
GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol (2010) 11.77
Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis. JAMA (2006) 11.71
Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010. Lancet (2012) 11.32
Magnetic resonance imaging profiles predict clinical response to early reperfusion: the diffusion and perfusion imaging evaluation for understanding stroke evolution (DEFUSE) study. Ann Neurol (2006) 10.51
The state of US health, 1990-2010: burden of diseases, injuries, and risk factors. JAMA (2013) 10.43
GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol (2011) 10.02
Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med (2001) 8.95
ATS/ACCP Statement on cardiopulmonary exercise testing. Am J Respir Crit Care Med (2003) 8.83
Randomized trials stopped early for benefit: a systematic review. JAMA (2005) 8.43
Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation (2009) 8.11
Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 7.94
Systems for grading the quality of evidence and the strength of recommendations I: critical appraisal of existing approaches The GRADE Working Group. BMC Health Serv Res (2004) 7.20
Concept, design and implementation of a cardiovascular gene-centric 50 k SNP array for large-scale genomic association studies. PLoS One (2008) 7.16
Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 7.12
Excess of rare variants in genes identified by genome-wide association study of hypertriglyceridemia. Nat Genet (2010) 7.08
Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet (2013) 7.03
High-frequency oscillation in early acute respiratory distress syndrome. N Engl J Med (2013) 6.56
Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation (2011) 6.36
Stopping randomized trials early for benefit and estimation of treatment effects: systematic review and meta-regression analysis. JAMA (2010) 5.90
Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 5.88
Probiotics for the prevention of Clostridium difficile-associated diarrhea: a systematic review and meta-analysis. Ann Intern Med (2012) 5.67
Comparison of mortality between private for-profit and private not-for-profit hemodialysis centers: a systematic review and meta-analysis. JAMA (2002) 5.57
Genetic Loci associated with C-reactive protein levels and risk of coronary heart disease. JAMA (2009) 5.32
A Trial of Wound Irrigation in the Initial Management of Open Fracture Wounds. N Engl J Med (2015) 5.28
Emerging risk factors for atherosclerotic vascular disease: a critical review of the evidence. JAMA (2003) 5.18
Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. BMJ (2008) 5.16
GRADE guidelines: 4. Rating the quality of evidence--study limitations (risk of bias). J Clin Epidemiol (2011) 5.10
Waist circumference and waist-to-hip ratio as predictors of cardiovascular events: meta-regression analysis of prospective studies. Eur Heart J (2007) 4.88
A systematic review and meta-analysis of studies comparing mortality rates of private for-profit and private not-for-profit hospitals. CMAJ (2002) 4.84
A systematic review of the evidence supporting a causal link between dietary factors and coronary heart disease. Arch Intern Med (2009) 4.80
Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N Engl J Med (2010) 4.73
Risk factors for venous thromboembolism. Circulation (2003) 4.64
Association of the metabolic syndrome with history of myocardial infarction and stroke in the Third National Health and Nutrition Examination Survey. Circulation (2003) 4.52
Evaluation of patients with pulmonary nodules: when is it lung cancer?: ACCP evidence-based clinical practice guidelines (2nd edition). Chest (2007) 4.49
Internet versus mailed questionnaires: a randomized comparison (2). J Med Internet Res (2004) 4.45
Subclavian artery stenosis: prevalence, risk factors, and association with cardiovascular diseases. J Am Coll Cardiol (2004) 4.43
Defining obesity cut points in a multiethnic population. Circulation (2007) 4.42
The diabetes mellitus medication choice decision aid: a randomized trial. Arch Intern Med (2009) 4.41
Need for expertise based randomised controlled trials. BMJ (2005) 4.34
Epidemiology of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest (2007) 4.29
Functional decline in peripheral arterial disease: associations with the ankle brachial index and leg symptoms. JAMA (2004) 4.27
An observational study of orthopaedic abstracts and subsequent full-text publications. J Bone Joint Surg Am (2002) 4.25
Sample design and cohort selection in the Hispanic Community Health Study/Study of Latinos. Ann Epidemiol (2010) 4.10
Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 4.01
Reconstructing angina: cardiac symptoms are the same in women and men. JAMA Intern Med (2013) 3.97
Fluid resuscitation in sepsis: a systematic review and network meta-analysis. Ann Intern Med (2014) 3.96
Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest (2004) 3.86
Combined corticosteroid and antiviral treatment for Bell palsy: a systematic review and meta-analysis. JAMA (2009) 3.81
Fasting triglyceride and the triglyceride-HDL cholesterol ratio are not markers of insulin resistance in African Americans. Arch Intern Med (2005) 3.81
A new 'mechanistic-practical" framework for designing and interpreting randomized trials. J Clin Epidemiol (2008) 3.75
The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 3.74
The reporting of methodological factors in randomized controlled trials and the association with a journal policy to promote adherence to the Consolidated Standards of Reporting Trials (CONSORT) checklist. Control Clin Trials (2002) 3.62
GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations. J Clin Epidemiol (2013) 3.58
Physicians' and patients' choices in evidence based practice. BMJ (2002) 3.57
Interventional pulmonary procedures: Guidelines from the American College of Chest Physicians. Chest (2003) 3.55
Is a subgroup effect believable? Updating criteria to evaluate the credibility of subgroup analyses. BMJ (2010) 3.54
The vexing problem of guidelines and conflict of interest: a potential solution. Ann Intern Med (2010) 3.47
Invasive mediastinal staging of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest (2007) 3.46
Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev (2011) 3.44
GRADE guidelines: 5. Rating the quality of evidence--publication bias. J Clin Epidemiol (2011) 3.44
Longer- Versus Shorter-Duration Dual-Antiplatelet Therapy After Drug-Eluting Stent Placement: A Systematic Review and Meta-analysis. Ann Intern Med (2015) 3.41
Measurement and interpretation of the ankle-brachial index: a scientific statement from the American Heart Association. Circulation (2012) 3.39